Ovarian Cancer Clinical Trial

Biobehavioral Intervention in Gynecologic Oncology Patients

Summary

Baseline self-report outcome measures will be completed and additional assessments will occur mid-treatment , post-treatment , 3 months following completion of all sessions, and 6 months following completion of all sessions. Patients and therapists will complete the evaluation measures in private (at home, in an office).

At the University of Kentucky Markey Cancer Center, BBI treatment is offered in group and individual formats. The course of individual treatment varies and group treatment consists of 10 1.5-hour weekly sessions in the "intensive" phase, followed by 2 1.5-hour bi-weekly maintenance sessions. Individual treatment is one-on-one. In group treatment, there are typically 6-12 patients per group and 1 or 2 therapists. The intervention helps patients to learn adaptive coping strategies and how to apply them to daily stressors. Additional content discusses use of seeking information, enhancing social support, enhancing body esteem and intimacy, and maintaining positive changes.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Females
Stage I-IV gynecologic cancer (including ovarian, uterine, cervical, vulvar, or vaginal cancer)
Undergoing active treatment or in remission and undergoing active surveillance; age ≥21 and ≤80
Able to speak/read English.

Exclusion Criteria:

Concurrent diagnosis of organic brain syndrome, dementia, mental retardation
Non-English speaking, or significant sensory deficit
Major mental illness (e.g., schizophrenia, psychotic disorder).

Study is for people with:

Ovarian Cancer

Phase:

Phase 2

Estimated Enrollment:

6

Study ID:

NCT02454036

Recruitment Status:

Completed

Sponsor:

Rachel Miller

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Markey Cancer Center, University of Kentucky
Lexington Kentucky, 40536, United States

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Phase:

Phase 2

Estimated Enrollment:

6

Study ID:

NCT02454036

Recruitment Status:

Completed

Sponsor:


Rachel Miller

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider